title: Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit.
abstract: OBJECTIVE
  To evaluate the risk of bacterial infection and use of antibiotics in otherwise healthy children infected with respiratory syncytial virus (RSV) admitted to the intensive care unit (ICU).
  
  
  METHODS
  Demographics, clinical information, interventions and outcomes were extracted from the charts of consecutive patients with laboratory-confirmed RSV infection at Children's Hospital, Boston from October 1990 through April 2002. Patients born at <36 weeks gestational age or with preexisting medical conditions were excluded.
  
  
  RESULTS
  The median age of the 165 previously healthy infants infected with RSV was 42 days. Almost all patients received supplementary FiO2, and 63 (38.2%) patients required mechanical ventilator support. No patients died. The median length of stay was 3 days in the ICU and 7 days in the hospital. Most patients had bacterial cultures sent: 155 (93.9%), blood cultures; 121 (73.3%), urine cultures; and 85 (51.5%) cerebrospinal fluid cultures. Only 1 blood culture was positive, and 1 potential urinary tract infection was identified in a patient with a negative urinalysis. All intubated patients and 80.4% of nonintubated patients received antibiotic therapy.
  
  
  CONCLUSIONS
  In otherwise healthy infants admitted to the ICU with RSV infection, bacteremia, urinary tract infection and meningitis are uncommon. Although bacterial pneumonia in this cohort may be more prevalent, overdiagnosis is common.
authors.affiliation: Department of Anesthesia, Harvard Medical School, Boston, MA, USA.
authors.forename: Adrienne G
authors.initials: AG
authors.lastname: Randolph
authors.forename: Lindsay
authors.initials: L
authors.lastname: Reder
authors.forename: Janet A
authors.initials: JA
authors.lastname: Englund
mesh_terms: D017677:Age Distribution; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D001769:Blood / Q000382:microbiology / Q000821:virology; D002675:Child, Preschool; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003422:Critical Care / Q000379:methods; D003428:Cross Infection / Q000175:diagnosis / Q000453:epidemiology*; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D015278:Intensive Care Units, Pediatric; D008297:Male; D011336:Probability; D012121:Respiration, Artificial; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D017678:Sex Distribution; D015163:Superinfection / Q000175:diagnosis / Q000453:epidemiology*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents